Hikma Pharmaceuticals (HIK) Insider Trading & Ownership GBX 1,894 -13.00 (-0.68%) As of 11:12 AM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock Hikma Pharmaceuticals (LON:HIK) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage30.54%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)£14,565.44Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)£49,986.00 Get HIK Insider Trade Alerts Want to know when executives and insiders are buying or selling Hikma Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address HIK Insider Buying and Selling by Quarter Remove Ads Hikma Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/8/2025Victoria HullInsiderSell2,777GBX 1,800£49,9865/7/2024Riad MishlawiInsiderBuy736GBX 1,979£14,565.44 (Data available from 1/1/2013 forward) HIK Insider Trading Activity - Frequently Asked Questions Who is on Hikma Pharmaceuticals's Insider Roster? The list of insiders at Hikma Pharmaceuticals includes Deneen Vojta, Douglas Hurt, Riad Mishlawi, and Victoria Hull. Learn more on insiders at HIK. What percentage of Hikma Pharmaceuticals stock is owned by insiders? 30.54% of Hikma Pharmaceuticals stock is owned by insiders. Learn more on HIK's insider holdings. Which Hikma Pharmaceuticals insiders have been buying company stock? The following insiders have purchased HIK shares in the last 24 months: Douglas Hurt (£27,300), and Riad Mishlawi (£14,565.44). How much insider buying is happening at Hikma Pharmaceuticals? Insiders have purchased a total of 2,236 HIK shares in the last 24 months for a total of £41,865.44 bought. Which Hikma Pharmaceuticals insiders have been selling company stock? The following insider sold HIK shares in the last 24 months: Victoria Hull (£49,986). How much insider selling is happening at Hikma Pharmaceuticals? Insiders have sold a total of 2,777 Hikma Pharmaceuticals shares in the last 24 months for a total of £49,986 sold. Hikma Pharmaceuticals Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Compensation: $2.21MMr. Riad Ali Mishlawi (Age 60)CEO & Director Compensation: $869.23kMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Compensation: $1.81MMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Patricia BousfieldChief Information OfficerMr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Samuel ParkGeneral CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive Vice President of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive Vice President of Strategic Planning & Global Affairs More Insider Trading Tools from MarketBeat Related Companies Indivior Insider Selling Alliance Pharma Insider Selling Venture Life Group Insider Selling ECO Animal Health Group Insider Selling Haleon Insider Selling Smith & Nephew Insider Selling ConvaTec Group Insider Selling Genus Insider Selling Oxford Nanopore Technologies Insider Selling Craneware Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Beware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market SentimentMicroStrategy Sees Insider Buy-Sell Action in Q1 This page (LON:HIK) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.